We are live on ! Find out more

Gilead Sciences

GILD

Market cap $210B

169.25 USD

-1.08

0.63%

At close Updated Nov 3, 3:12 PM EST

1 day

-0.63%

5 days

7.61%

1 month

17.02%

3 months

29.05%

6 months

27.55%

Year to date

39.19%

1 year

38.67%

5 years

151.08%

10 years

135.86%

About: Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Employees: 17,000

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 57.1%

Neutral 36.7%

Negative 6.1%

Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2026), taking place from November 8-11. As a leader in HIV innovation, Gilead will share new clinical data and real-world evidence from its HIV research and development programs and provide updates on its strategic initiatives and key collaborations. Results from more than 50 studies, including late-brea.

Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow

Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:Wolfe Research Healthcare Conference on Tuesday, November 10 at 11:20 AM Eastern TimeUBS Global Biopharma Conference on Tuesday, November 17 at 10:00 AM Greenwich Mean TimeJefferies Global Healthcare Conference on Tuesday, November 17 at 2:30 PM Greenwich Mean TimeCiti's Global Healthcare Conference on Tuesday, December 1 at 11:00 A.

Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences

Gilead: Q3 Earnings Overview - It's Time To Consider Selling After Stellar Year

Gilead Sciences, Inc. delivered its strongest growth in a decade, with Q3 revenues up 16% ex-Veklury and robust HIV franchise performance. GILD's HIV division remains dominant, but Biktarvy faces 2028 Medicare price controls, expected to reduce revenue by $1.5bn that year. Oncology and immunology franchises lag, with mixed M&A results and limited near-term growth outside HIV despite heavy investment.

Gilead: Q3 Earnings Overview - It's Time To Consider Selling After Stellar Year

Zacks Investment Research

GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales Growth

Gilead tops Q3 earnings and revenue estimates as HIV sales, Trodelvy and Livdelzi drive growth, prompting an increase in 2026 product sales guidance.

GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales Growth

Zacks Investment Research

GILD Q3 Earnings Call Highlights Raised Outlook and Pricing Risks

Gilead Sciences, Inc. GILD raised its 2026 sales outlook following strong third-quarter growth while providing new details on a significant Biktarvy pricing headwind expected in 2028.

GILD Q3 Earnings Call Highlights Raised Outlook and Pricing Risks

Gilead: The Business Is Growing, But The Valuation No Longer Works

Gilead Sciences faces valuation headwinds despite strong Q3 results and successful HIV, Trodelvy, and Yeztugo growth. Medicare pricing will reduce Biktarvy revenue by $1.5 billion annually starting in 2028, intensifying GILD's dependence on HIV. Q3 HIV growth was inflated by inventory build and a favorable channel mix, making it unsustainable for future quarters.

Gilead: The Business Is Growing, But The Valuation No Longer Works

Gilead Sciences: Why I Remain Bullish After Q3

Gilead Sciences had a strong Q3. Sales of Trodelvy, a Trop-2-directed antibody-drug conjugate approved for the treatment of breast cancer, were $506 million, up 41.7% YoY and 10.7% QoQ. On October 22, Gilead agreed to acquire PepStar's oral IL-23R inhibitor program, including HCXT-2001, for $1.275 billion upfront.

Gilead Sciences: Why I Remain Bullish After Q3

These Analysts Increase Their Forecasts On Gilead Sciences After Upbeat Q3 Results

Gilead Sciences, Inc. (NASDAQ:GILD) reported better-than-expected earnings for the third quarter on Thursday.

These Analysts Increase Their Forecasts On Gilead Sciences After Upbeat Q3 Results

Gilead Sciences, Inc. (GILD) Q3 2026 Earnings Call Transcript

Gilead Sciences, Inc. ( GILD ) Q3 2026 Earnings Call October 29, 2026 4:30 PM EDT Company Participants Jacquie Ross - Senior Vice President of Treasury & Investor Relations Daniel O'Day - Chairman & CEO Johanna Mercier - Chief Commercial & Corporate Affairs Officer Dietmar Berger - Chief Medical Officer Andrew Dickinson - Executive VP & CFO Cindy Perettie - Executive Vice President of Kite Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Akash Tewari - Jefferies LLC, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Brian Abrahams - RBC Capital Markets, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Michael Yee - UBS Investment Bank, Research Division Terence Flynn - Morgan Stanley, Research Division Daina Graybosch - Leerink Partners LLC, Research Division Louise Chen - Scotiabank Global Banking and Markets, Research Division Carter Gould - Cantor Fitzgerald & Co., Research Division Geoffrey Meacham - Citigroup Inc., Research Division Presentation Operator Good afternoon, everyone, and welcome to Gilead's Third Quarter 2026 Earnings Conference Call. My name is Rebekah, and I'll be today's host.

Gilead Sciences, Inc. (GILD) Q3 2026 Earnings Call Transcript

Zacks Investment Research

Gilead (GILD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Gilead (GILD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

See News Rankings

Price charts implemented using Lightweight Charts™